NEW YORK, May 23, 2026, 14:03 EDT
- AbbVie wrapped up Friday at $215.70, adding 0.56%. Shares climbed roughly 2.5% for the week.
- Markets are shut on Monday for Memorial Day. Trading on the NYSE picks back up later this week when ASCO cancer data will be in the spotlight.
- AbbVie news this week touched hepatitis C, oncology and aesthetics, though a number of catalysts now depend on new clinical or regulatory moves.
AbbVie Inc. shares climbed ahead of the U.S. holiday weekend, lifted by a stronger market and several drug-pipeline updates that gave investors new info before cancer meetings next week.
The stock edged up 0.56% to finish Friday at $215.70, with volume at 5.41 million shares. That put shares roughly 2.5% above last week’s close of $210.39, based on market data.
That comes up now as U.S. markets close for Memorial Day on Monday. Traders will have to price AbbVie’s new regulatory and trial updates when the New York Stock Exchange opens next. NYSE puts Memorial Day on Monday, May 25, for its 2026 holiday schedule.
U.S. stocks closed higher Friday, with the S&P 500 finishing up 0.37% and the Dow adding 0.58%. Johnson & Johnson (JNJ) ended the day up 1.13%. Pfizer (PFE) fell 0.19%. AbbVie (ABBV) rose 0.56%, landing between its pharma rivals.
AbbVie said Friday a panel at the European Medicines Agency backed MAVIRET for treatment of acute hepatitis C in adults and kids 3 years and up. The CHMP, or Committee for Medicinal Products for Human Use, handles these reviews before a final call by the European Commission.
Primal Kaur, AbbVie’s senior vice president for global development, said the recommendation is an “important step toward enabling earlier treatment.” AbbVie said it expects a decision from the European Commission in the third quarter. AbbVie News Center
The drug has EU approval for chronic hepatitis C. AbbVie reported Phase 3 results in acute hepatitis C, showing a 96.2% SVR12 rate—patients had no detectable virus 12 weeks after treatment, a standard cure measure in hepatitis C trials.
ASCO kicks off this week in Chicago. AbbVie said Thursday it plans to show data on antibody-drug conjugates and T-cell engagers, both aimed at fighting cancer. The antibody-drug conjugates use an antibody to deliver a toxin to tumor cells, while T-cell engagers direct immune cells to cancer.
AbbVie’s oncology therapeutic-area head Daejin Abidoye said the ASCO results showed “continued momentum with our ADC programs.” For ABBV-969 in metastatic castration-resistant prostate cancer, AbbVie saw a 45% confirmed objective response rate out of 29 evaluable patients. The company also posted an 82% response rate for ABBV-706 in a 17-patient small-cell lung cancer group. AbbVie News Center
Allergan Aesthetics, AbbVie’s aesthetics arm, picked up a positive CHMP opinion for Boey, its short-acting botulinum toxin aimed at glabellar lines, or frown lines between the brows. AbbVie chief scientific officer Roopal Thakkar said the product shows the company’s efforts “advancing botulinum toxin science.” AbbVie News Center
AbbVie’s pipeline update comes as investors focus on how well the company can make up for falling Humira sales with new drugs. In its first-quarter earnings on April 29, AbbVie posted revenue of $15.00 billion, a 12.4% gain. Skyrizi sales jumped 30.9%. Rinvoq was up 23.3%. Humira dropped 38.6%. CEO Robert Michael said the quarterly numbers beat AbbVie’s own outlook.
Still, the risk isn’t off the table. The European Commission hasn’t finalized decisions for the CHMP-supported products, and many of the ASCO results come from smaller, early-phase trials that need bigger studies before investors can shift their forecasts. A soft overall market after the holiday, or letdowns from cancer trial data later this week, could take most of Friday’s move away.
